mpn transformation to mds and aml: risk factors, therapy, and outcomes
Published 8 years ago • 891 plays • Length 20:58Download video MP4
Download video MP3
Similar videos
-
20:12
mpn transformation to mds and aml: risk factors, therapy and outcomes
-
23:38
why mpns transform to aml
-
23:39
why mpn transforms to aml
-
27:35
expert perspectives: mpn and mds
-
17:53
biology of aml developing from mds vs. de novo aml, and new targets for therapy
-
24:30
key insights: mpn and mds
-
14:55
high-risk myelodysplastic syndromes and low-blast acute myeloid leukemia: q&a
-
21:55
a unified approach to lower risk mds: standard and emerging therapies
-
25:48
the who updated diagnostic criteria for mpn
-
21:33
therapeutic insights in clonal evolution of mpn to accelerated or blastic phase
-
24:04
my approach to mds management
-
23:53
updates in leukemia, mpn, and mds
-
17:56
expert perspectives: myeloproliferative neoplasms & mds
-
1:10:32
mds/mpn/aml session
-
10:30
mds/mpn
-
22:27
influence of mutational status on timing, outcome, and post-transplant management of myelofibrosis
-
18:36
diagnostic challenges in mpn
-
33:47
my approach to mds management